CHAPEL HILL, N.C., May 7 /PRNewswire/ -- In today's marketplace, pharmaceutical and biotechnology companies are experiencing intense pricing, political, regulatory and market pressures. These forces are creating stress on the industry's fundamental business model. Consequently, pharmaceutical and biotechnology companies must evaluate the optimal levels of human and capital investment in the commercial enterprise to ensure health and competitiveness.
Due to increasing prices and shrinking margin pressures, few, if any,
companies can ignore how many people they staff to critical functions. Best
Practices, LLC's benchmarking study analyzes resource allocation specific
to key business functions in the pharmaceutical and biotechnology
industries and can further assist business unit managers in assessing their
level of staffing investment and resources channeled into different
A sample of analyzed functions in the report is:
-- Marketing -- this is further segmented, analyzed, and benchmarked on
the basis of product
-- State Government Affairs -- benchmarking data segmented by sales
revenues provide greater insight and highlights trends
-- Finance -- segmented and benchmarked by sales revenues to provide
greater insight and trends
If you have to defend or validate budget and staffing resource decisions, the Best Practices Pharmaceutical Budget and Staffing Benchmark Guide will prove invaluable. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.
To download a free excerpt of U.S. Pharmaceutical Budget and Staffing
Excellence visit http://www3.best-in-class.com/rr
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved